FDA Grants Rare Pediatric Disease Designation to PAS-004 for NF1 Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 19 hours ago
0mins
Should l Buy KTTA?
Source: NASDAQ.COM
- FDA Designation Progress: Pasithea Therapeutics' PAS-004 has received Rare Pediatric Disease Designation from the FDA for Neurofibromatosis Type 1 (NF1), marking a significant milestone in the company's drug development journey.
- Priority Review Voucher Potential: This designation makes PAS-004 eligible for a Priority Review Voucher upon approval, with recent voucher sales ranging from $150 million to $205 million, potentially providing substantial financial benefits to the company.
- Clinical Trial Advancement: A Phase 1/1b study of PAS-004 is currently underway, targeting adult patients with symptomatic, inoperable, or recurrent NF1-related plexiform neurofibromas, demonstrating the company's proactive exploration in the treatment space.
- Stock Performance: Pasithea's stock closed at $0.7424 on Friday, up 0.87%, reflecting the market's positive response to the company's drug development progress.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KTTA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KTTA
Wall Street analysts forecast KTTA stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.742
Low
3.00
Averages
3.00
High
3.00
Current: 0.742
Low
3.00
Averages
3.00
High
3.00
About KTTA
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Grants Rare Pediatric Disease Designation to PAS-004 for NF1 Treatment
- FDA Designation Progress: Pasithea Therapeutics' PAS-004 has received Rare Pediatric Disease Designation from the FDA for Neurofibromatosis Type 1 (NF1), marking a significant milestone in the company's drug development journey.
- Priority Review Voucher Potential: This designation makes PAS-004 eligible for a Priority Review Voucher upon approval, with recent voucher sales ranging from $150 million to $205 million, potentially providing substantial financial benefits to the company.
- Clinical Trial Advancement: A Phase 1/1b study of PAS-004 is currently underway, targeting adult patients with symptomatic, inoperable, or recurrent NF1-related plexiform neurofibromas, demonstrating the company's proactive exploration in the treatment space.
- Stock Performance: Pasithea's stock closed at $0.7424 on Friday, up 0.87%, reflecting the market's positive response to the company's drug development progress.
See More
Pasithea Receives Rare Pediatric Disease Designation for PAS-004
- FDA Designation Progress: Pasithea Therapeutics' PAS-004 has received Rare Pediatric Disease Designation from the FDA for Neurofibromatosis type 1 (NF1), indicating the drug's potential to address this serious condition affecting approximately 115,000 individuals in the U.S.
- Priority Review Voucher Opportunity: Under the FDA's Priority Review Voucher program, drugs receiving this designation may obtain priority review for subsequent applications, with vouchers previously selling for between $150 million and $205 million in the last year, highlighting significant market potential.
- Clinical Trial Advancement: The company is currently conducting a Phase 1/1b multicenter open-label dose escalation trial of PAS-004 in adult NF1 patients, aimed at assessing the drug's safety and preliminary efficacy, further advancing its clinical development.
- Multiple FDA Designations: PAS-004 has secured Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation, showcasing its broad application potential in treating RASopathies and MAPK pathway-driven tumors, thereby enhancing the company's competitive position in the biotechnology sector.
See More
Pasithea Receives FDA Fast Track Designation for PAS-004
- FDA Fast Track Designation: Pasithea Therapeutics' PAS-004 has received Fast Track designation from the FDA for treating NF1-associated PN, a decision that will expedite drug development and significantly enhance patient access and timeliness of treatment.
- Clinical Trial Progress: The company is currently conducting a Phase 1/1b multicenter open-label dose escalation trial of PAS-004 in adult patients with symptomatic, inoperable, incompletely resected, or recurrent NF1-PN, which is expected to provide new treatment options for patients.
- Market Potential: With 30-50% of NF1 patients harboring PNs that may undergo malignant transformation, the development of PAS-004 not only addresses this unmet medical need but also opens new market opportunities for Pasithea, enhancing its competitiveness in the biotechnology sector.
- FDA Interaction Advantages: The Fast Track designation allows Pasithea to engage in frequent communications with the FDA, supporting rapid feedback during the product development process, thereby improving the efficiency and success rate of clinical trials and further strengthening the company's strategic position in the biopharmaceutical industry.
See More
Pasithea to Present Drug Progress at Oppenheimer Conference
- CEO Presentation Scheduled: Pasithea's CEO Tiago Reis Marques is set to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, from 4:00 to 4:30 PM, showcasing the latest developments in the company's drug pipeline, which is expected to attract investor interest.
- Clinical Trial Updates: The company is conducting Phase 1 trials for PAS-004 targeting advanced cancer patients (NCT06299839) and adult patients with neurofibromatosis type 1 (NF1) (NCT06961565), which will lay the groundwork for future drug approvals and enhance market competitiveness.
- Investor Engagement Opportunities: Management will be available for one-on-one meetings with registered investors during the conference, providing direct engagement that not only boosts investor confidence but may also facilitate future financing opportunities.
- Live Webcast Availability: The presentation will be accessible via a live webcast on the company's investor section of the website, with a replay available post-event, ensuring that investors who cannot attend live can still access critical information, thereby enhancing company transparency and investor relations.
See More
Pasithea Therapeutics Closes $60M Public Offering of 80M Shares
- Successful Financing: Pasithea Therapeutics has completed a public offering of 80 million shares at $0.75 per share, raising approximately $60 million, which enhances the company's financial strength to support future R&D and clinical trials.
- Cash Runway Extension: This financing is expected to extend the company's cash runway through at least the first half of 2028, ensuring ongoing investment in new drug development and clinical trials, thereby enhancing market competitiveness.
- Clear Investment Direction: The company plans to use the proceeds for general corporate purposes, including ongoing research, clinical trials, and acquiring companies that complement its technologies, aiming to accelerate technological development and market expansion.
- Increased Market Confidence: The offering was led by several healthcare-focused investors, indicating strong market confidence in Pasithea's future development, which may attract more investor interest in its subsequent progress.
See More
Vision Marine Technologies Stock Rises Over 10%; Check Out 20 Stocks Making Moves in Premarket Trading
Vision Marine Technologies Performance: Vision Marine Technologies Inc. shares rose 10.5% to $1.36 in pre-market trading after announcing strong financial results for the fiscal year ending August 31, 2025, and highlighting strategic expansion following the acquisition of Nautical Ventures, which generated $12.8 million in revenue.
Other Gainers in Pre-Market Trading: Several stocks saw significant gains in pre-market trading, including WEBUY Global Ltd. (+62.1%), Direct Digital Holdings, Inc. (+60.6%), and INVO Fertility, Inc. (+24.7%), with various companies announcing acquisitions or strategic plans.
Notable Losers in Pre-Market Trading: SMX (Security Matters) PLC experienced a sharp decline of 24.6% after a previous surge, while Springview Holdings Ltd. fell 20.7% following a reverse share split announcement.
Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies like New Fortress Energy Inc. and Canadian Solar Inc. also reporting notable increases.
See More
FDA Grants Rare Pediatric Disease Designation to PAS-004 for NF1 Treatment
- FDA Designation Progress: Pasithea Therapeutics' PAS-004 has received Rare Pediatric Disease Designation from the FDA for Neurofibromatosis Type 1 (NF1), marking a significant milestone in the company's drug development journey.
- Priority Review Voucher Potential: This designation makes PAS-004 eligible for a Priority Review Voucher upon approval, with recent voucher sales ranging from $150 million to $205 million, potentially providing substantial financial benefits to the company.
- Clinical Trial Advancement: A Phase 1/1b study of PAS-004 is currently underway, targeting adult patients with symptomatic, inoperable, or recurrent NF1-related plexiform neurofibromas, demonstrating the company's proactive exploration in the treatment space.
- Stock Performance: Pasithea's stock closed at $0.7424 on Friday, up 0.87%, reflecting the market's positive response to the company's drug development progress.
See More
Pasithea Receives Rare Pediatric Disease Designation for PAS-004
- FDA Designation Progress: Pasithea Therapeutics' PAS-004 has received Rare Pediatric Disease Designation from the FDA for Neurofibromatosis type 1 (NF1), indicating the drug's potential to address this serious condition affecting approximately 115,000 individuals in the U.S.
- Priority Review Voucher Opportunity: Under the FDA's Priority Review Voucher program, drugs receiving this designation may obtain priority review for subsequent applications, with vouchers previously selling for between $150 million and $205 million in the last year, highlighting significant market potential.
- Clinical Trial Advancement: The company is currently conducting a Phase 1/1b multicenter open-label dose escalation trial of PAS-004 in adult NF1 patients, aimed at assessing the drug's safety and preliminary efficacy, further advancing its clinical development.
- Multiple FDA Designations: PAS-004 has secured Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation, showcasing its broad application potential in treating RASopathies and MAPK pathway-driven tumors, thereby enhancing the company's competitive position in the biotechnology sector.
See More
Pasithea Receives FDA Fast Track Designation for PAS-004
- FDA Fast Track Designation: Pasithea Therapeutics' PAS-004 has received Fast Track designation from the FDA for treating NF1-associated PN, a decision that will expedite drug development and significantly enhance patient access and timeliness of treatment.
- Clinical Trial Progress: The company is currently conducting a Phase 1/1b multicenter open-label dose escalation trial of PAS-004 in adult patients with symptomatic, inoperable, incompletely resected, or recurrent NF1-PN, which is expected to provide new treatment options for patients.
- Market Potential: With 30-50% of NF1 patients harboring PNs that may undergo malignant transformation, the development of PAS-004 not only addresses this unmet medical need but also opens new market opportunities for Pasithea, enhancing its competitiveness in the biotechnology sector.
- FDA Interaction Advantages: The Fast Track designation allows Pasithea to engage in frequent communications with the FDA, supporting rapid feedback during the product development process, thereby improving the efficiency and success rate of clinical trials and further strengthening the company's strategic position in the biopharmaceutical industry.
See More
Pasithea to Present Drug Progress at Oppenheimer Conference
- CEO Presentation Scheduled: Pasithea's CEO Tiago Reis Marques is set to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, from 4:00 to 4:30 PM, showcasing the latest developments in the company's drug pipeline, which is expected to attract investor interest.
- Clinical Trial Updates: The company is conducting Phase 1 trials for PAS-004 targeting advanced cancer patients (NCT06299839) and adult patients with neurofibromatosis type 1 (NF1) (NCT06961565), which will lay the groundwork for future drug approvals and enhance market competitiveness.
- Investor Engagement Opportunities: Management will be available for one-on-one meetings with registered investors during the conference, providing direct engagement that not only boosts investor confidence but may also facilitate future financing opportunities.
- Live Webcast Availability: The presentation will be accessible via a live webcast on the company's investor section of the website, with a replay available post-event, ensuring that investors who cannot attend live can still access critical information, thereby enhancing company transparency and investor relations.
See More
Pasithea Therapeutics Closes $60M Public Offering of 80M Shares
- Successful Financing: Pasithea Therapeutics has completed a public offering of 80 million shares at $0.75 per share, raising approximately $60 million, which enhances the company's financial strength to support future R&D and clinical trials.
- Cash Runway Extension: This financing is expected to extend the company's cash runway through at least the first half of 2028, ensuring ongoing investment in new drug development and clinical trials, thereby enhancing market competitiveness.
- Clear Investment Direction: The company plans to use the proceeds for general corporate purposes, including ongoing research, clinical trials, and acquiring companies that complement its technologies, aiming to accelerate technological development and market expansion.
- Increased Market Confidence: The offering was led by several healthcare-focused investors, indicating strong market confidence in Pasithea's future development, which may attract more investor interest in its subsequent progress.
See More
Vision Marine Technologies Stock Rises Over 10%; Check Out 20 Stocks Making Moves in Premarket Trading
Vision Marine Technologies Performance: Vision Marine Technologies Inc. shares rose 10.5% to $1.36 in pre-market trading after announcing strong financial results for the fiscal year ending August 31, 2025, and highlighting strategic expansion following the acquisition of Nautical Ventures, which generated $12.8 million in revenue.
Other Gainers in Pre-Market Trading: Several stocks saw significant gains in pre-market trading, including WEBUY Global Ltd. (+62.1%), Direct Digital Holdings, Inc. (+60.6%), and INVO Fertility, Inc. (+24.7%), with various companies announcing acquisitions or strategic plans.
Notable Losers in Pre-Market Trading: SMX (Security Matters) PLC experienced a sharp decline of 24.6% after a previous surge, while Springview Holdings Ltd. fell 20.7% following a reverse share split announcement.
Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies like New Fortress Energy Inc. and Canadian Solar Inc. also reporting notable increases.
See More
